ORGANIZATION
Generic Industry Can’t Afford “Backsliding” Following FY2014 NHI Pricing Reform: JGA President Yoshida
Japan Generic Medicines Association (JGA) President Itsuro Yoshida has reiterated his view that the NHI price revision scheduled for this April, which will include a new 60% pricing rule for first generics and the listing of three prices for generics…
To read the full story
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





